Myelodysplastic Syndrome: Recent Advances and Future Directions
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: closed (20 July 2022) | Viewed by 10145
Special Issue Editor
Special Issue Information
Dear Colleagues,
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem-cell disorders that prevail in elderly patients. They manifest with the development of cytopenias and have a variable tendency for leukemic transformation. With the availability of next-generation sequencing, recurrent somatic mutations in genes involved in epigenetic regulation, RNA splicing, TP53, transcriptional regulation and signal transduction have been identified and have paved the way for the development of individualized treatment. Currently approved drugs for the treatment of MDS include those aimed at reducing the transfusion burden and improving anemia (recombinant erythropoietin, lenalidomide and luspatercept) for lower-risk disease and hypomethylating agents (HMA) to prolong survival in higher-risk MDS. However, these are not curative treatments, so the only possible cure remains allogeneic stem-cell transplantation. Patients eligible for clinical trials may benefit from investigational drugs. Treatments must aim at maintaining or improving health-related quality of life. This Special Edition has been designed to review MDS patients’ unmet needs and will provide the reader with a broadened understanding of novel biological findings integrated with present and future treatment options and their outcomes.
Dr. Esther Natalie Oliva
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- myelodysplastic syndromes
- quality of life
- next-generation sequencing
- IPSS-R
- hypomethylating agents
- anemia
- transfusions
- cytopenia
- hypomethylating agents
- immunotherapy
- biological modifiers